Protocol No.: M16-000

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991.
Principal Investigator
Kupec, Justin
Phase
III
Age Group
Adult
Applicable Disease Site
Digestive Disease
Participating Institution
Health Sciences Center
Contact
Jada Heath-Granger
Phone: +1 304-293-7015

View on ClinicalTrials.gov